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In recent years, the explosive spread of antibiotic resistance determinants among pathogenic, commensal,
and environmental bacteria has reached a global dimension. Classical measures trying to contain or slow
locally the progress of antibiotic resistance in patients on the basis of better antibiotic prescribing policies have
clearly become insufficient at the global level. Urgent measures are needed to directly confront the processes
influencing antibiotic resistance pollution in the microbiosphere. Recent interdisciplinary research indicates
that new eco-evo drugs and strategies, which take ecology and evolution into account, have a promising role in
resistance prevention, decontamination, and the eventual restoration of antibiotic susceptibility. This minire-
view summarizes what is known and what should be further investigated to find drugs and strategies aiming
to counteract the “four P’s,” penetration, promiscuity, plasticity, and persistence of rapidly spreading bacterial
clones, mobile genetic elements, or resistance genes. The term “drug” is used in this eco-evo perspective as a
tool to fight resistance that is able to prevent, cure, or decrease potential damage caused by antibiotic
resistance, not necessarily only at the individual level (the patient) but also at the ecological and evolutionary
levels. This view offers a wealth of research opportunities for science and technology and also represents a large
adaptive challenge for regulatory agencies and public health officers. Eco-evo drugs and interventions consti-
tute a new avenue for research that might influence not only antibiotic resistance but the maintenance of a
healthy interaction between humans and microbial systems in a rapidly changing biosphere.
Insufficiency of current measures to control the emergence,
selection, and spread of antimicrobial resistance. Antibiotic
resistance (AbR) is widespread in nature, and the goal of
eliminating all resistance genes is simply nonsense, as the nat-
ural function of most resistance genes has nothing to do with
AbR (91). Most probably, there is a huge “intrinsic resistome”
in bacterial organisms, composed of genes of varied phyloge-
netic origin that act as resistance genes only in the presence of
the antibiotic (48, 60, 126). Cleansing nature of this gene pool
is impossible. The most we can do is to try to control the
emergence, selection, and spread of AbR genes in bacterial
organisms interacting with humans, animals, or plants (158).
The classical methods of controlling the emergence and spread
of AbR are based on the discovery of new antimicrobial agents
(mostly in genocentric research) (52, 158), reduction of chronic
antibiotic-promoted bacterial mutagenic stress, recombination,
and horizontal-transfer genetic events associated with low dos-
ages (29, 82, 109, 143), suppression of phenotypic resistance
(34, 119, 154), use of combinations of drugs (16, 28, 44), in-
cluding antagonistic drug pairs (92, 140), early intensive (front-
line) therapy, maintaining a low bacterial density (44, 47, 51),
and more recently, surveillance of hypermutable organisms
(85) and targeting controlling functions essential for infection
(26, 32, 61, 112). Controlling selection of AbR is a major
practical goal, which can be addressed again by the develop-
ment of novel anti-infective drugs and the appropriate use of
antibiotics, avoiding low dosages able to select low-level mu-
tations that can also serve as stepping stones for high-level
resistance (9, 10, 45). Major efforts have been made to reduce
general overconsumption of antimicrobial agents and thus
limit the exposure of eventual resistant variants of pathogenic
and commensal bacteria to the high-intensity selective power
of these agents (53). Finally, a classical approach to avoid the
spread of AbR is based on general hygiene and containment
(infection control) measures, decreasing contact between pa-
tients contaminated (infected or carriers) with resistant bacte-
ria and noncontaminated patients (17, 18).
Unfortunately, these measures are becoming increasingly
insufficient in the current global landscape of AbR (19, 106,
124). Avoiding the emergence of resistance in the individual
patient is obviously important for the individual, but it has
minimal effects in the community (123). The efficacy of classi-
cal methods of controlling selection and spread is inversely
proportional to the density and penetration (discussed below)
(33) of resistant organisms and their mobile genetic elements
in particular environments. Measures that might be successful
in early stages of the development of resistance or in hospitals
or countries with low rates of AbR have no value in areas
where resistance is already an established biological phenom-
enon (18, 115). Even in areas with low levels of AbR pollution,
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such as Sweden, recent studies have shown that a 2-year dis-
continuation of trimethoprim use had no influence at all on the
Escherichia coli resistance rates (134). This was probably due
to the widespread distribution of trimethoprim resistance
genes (dfr) in replicons harboring other resistance determi-
nants, thus ensuring coselection of dfr genes with other resis-
tance genes (20). Some regions of the world are densely pol-
luted with AbR, while others remain clean (63, 137). In a
global world, sooner or later, resistance originating in these
highly contaminated “sources of resistance” will invade envi-
ronments that are still clean (137, 158). Some models suggest
that there is a threshold for this phenomenon. One of these
models shows that resistant organisms are constantly diluted
and potentially extinguish in competition with constant immi-
gration of susceptible bacteria in local environments, but such
a trend might collapse due to the increase of resistant popu-
lations (16). Moreover, the success of resistant organisms con-
tributes to the constant accumulation in the bacterial world of
genetic platforms and vehicles able to efficiently recruit and
spread novel resistance genes. AbR calls for more resistance
and increases bacterial genetic evolvability in a phenomenon
described as “genetic capitalism” (7). At this time, resistance
might be reversible by current interventions only when it is
rare; if resistance is frequent, reversibility is not to be expected.
Eco-evo strategies: a novel integrative approach. The eco-
evo concept started to be discussed in the last several years (39,
103). The eco-evo concept can be defined as a perspective in
which organisms are evaluated broadly in the light of evolution
and ecology, rather than narrowly by the constraints of their
behavior in the laboratory or in the clinical practice in relation
to human infections (103). The concept was coined first to
explain the shift in bacterial life histories from commensal to
pathogenic organisms (39). This notion also applies to AbR. In
the scope of this minireview, we apply the term eco-evo strat-
egies for the strategies leading to interventions that aim not
necessarily to kill resistant organisms but rather to prevent
their emergence and evolution or to reestablish the antibiotic-
susceptible populations. It should be pointed out that at this
time, most of the possible eco-evo strategies remain highly
speculative, and few of them have been tested in the field.
However, they are frequently based on well-documented novel
knowledge. At this time, data are accumulating about the pop-
ulation genetics not only of bacterial pathogenic and antibiotic-
resistant species and clones but also of the mobile genetic
elements (MGEs) transporting resistance genes and associated
platforms, such as plasmids, transposons, or integrative conju-
gative elements (ICEs) (22, 55, 121, 122, 135, 157). We are also
making continuous progress in the field of bacterial ecogenet-
ics, a field of biological research that studies the role of genetic
variation in response to variable environments (101) and in the
field of pharmacogenomics combined with systems biology,
bioinformatics, and patient treatment (32, 70, 100, 118, 158).
The use of antibiotics not only selects for resistant bacteria,
MGEs carrying resistance genes, and even particular se-
quences within these genes, but it also promotes the movement
of genes and competence for genetic transformation (29, 30,
109). Indeed, antibiotics produce an effect that should be an-
alyzed under the light of the multilevel selection theory, a new
burst of neo-Darwinian approaches (146). Selection naturally
changes the ecological context, as it modifies population ecol-
ogy, which influences the whole evolution of microbial systems
(5, 21). Therefore, not only resistant bacteria should be con-
sidered units of epidemiological surveillance of AbR, all other
elements (pieces) able to shape the natural evolutionary his-
tory of AbR should also be considered (3, 121). Consequently,
all these biological-genetic elements, at any level of the hier-
archy, should become targets for intervention against AbR.
Note that these genetic elements are frequently linked by co-
operative interactions, so that altering the density of particular
bacterial clones should have consequences on the selection and
evolution of MGEs (74, 96, 110).
Such a perspective indicates the need and possibility of using
“eco-evo” drugs, drugs acting not necessarily to cure the indi-
vidual patient (although this might happen for some antiviru-
lence eco-evo drugs) but to “cure” specific environments from
AbR and to prevent or weaken the evolutionary possibilities
(the evolvability) of the biological elements involved in AbR.
In other words, this perspective proposes to combat (decon-
taminate, de-evolve) resistance not only in infected patients
but in a whole population composed of infected and nonin-
fected people alike, as occurs in hospitals, nurseries, or elderly
care facilities, as well as in general hot environments (“resis-
tance reactors”), facilitating the evolution of AbR (8, 159). By
extension, other environments that can be successfully treated
are farms, fish factories, and eventually water effluents. Indeed,
the notion of an “ill environment” should be increasingly en-
couraged, and medical treatment-like approaches might be
increasingly applied to prevent and cure biologically altered
environments (6, 89, 114, 159).
General targets for eco-evo drugs and strategies. The ecol-
ogy and evolution of AbR depend on the construction of in-
teractive networks able to exchange resistance genes between
organisms, and/or among MGEs and their platforms, as well as
their intrinsic variability (3, 21, 62a, 96, 121, 149). Such variable
networks ensure joint evolution at multiple levels, a kind of
multilevel cooperation. The bases of such cooperation are con-
nectivity and variability, the general target processes for eco-
evo drugs. Expanding this view, at any level of the hierarchy
(let us say, from clones to plasmids or genes), the ecology and
evolution of antimicrobial resistance depend on the “four P’s”,
the penetration, promiscuity, plasticity, and persistence of the
different genetic units. The word “penetration” is used here, by
analogy with the term used in security engineering, for ele-
ments having a high attack profile regarding existing networks
(33) and refers to the ability of a genetic element from a
particular system to enter and be present in other systems.
Examples are bacterial clones able to efficiently colonize and
spread in microbiomes of different hosts or broad-host-range
plasmids disseminating in widely different bacteria. The term
“promiscuity” refers to the abilities to not only enter and be
present in other systems but to exchange genetic sequences
with the members of the system. The word “plasticity” is ap-
plied here as tolerated variability in the genetic sequences,
from changes in the sequence of nucleotides in a gene to
changes in the order of genes in a genome (syntheny) or
changes in the modular structure of genetic regions (modular-
ity) or in the modulation of their expression. An example of
this is the change in the order of gene cassettes within a
particular integron. The word “persistence” is used for the
ability of each one of the biological elements to “construct a
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niche,” so that permanent links with its surrounding environ-
ment (including the genetic context) are established, allowing
long-term coexistence or fixation of the sequence or element in
the system. In the following paragraphs, we review possible
eco-evo drugs or interventions directed against each one of
these four eco-evolutionary frames. A comprehensive list of
these drugs and interventions is presented in Table 1.
Penetration inhibitors. (i) Inhibitors of high-risk bacterial
clones. The local or global prevalence of AbR frequently de-
pends on the local or global dissemination of particular bacte-
rial clones which have been named high-risk antibiotic-resis-
tant bacterial clones, eventually clustered in clonal complexes
(152, 155). Note that the term “high-risk” is not necessarily
associated here with clones causing severe infections. The
“high-risk” clone emerges when a clone with high interhost
transmission and colonization efficiency acquires an antibiotic
resistance trait. Well-established examples of such clones (mul-
tilocus sequence clonal complexes [CCs] or sequence types
[STs]) among Gram-positive bacteria are Streptococcus pneu-
moniae clonal complex 256 (CC256) and CC15 clones involved
in the spread of beta-lactam and macrolide resistance, methi-
cillin-resistant Staphylococcus aureus belonging to CC8 (se-
quence type 8 [ST8], ST239, and ST247), CC22 (ST22), CC5
(ST5 and ST228), CC45 (ST45), and CC30 (ST36); vancomy-
cin- and/or ampicillin-resistant Enterococcus faecium belonging
to the CC17 polyclonal subcluster (ST16, ST17, ST18 among
others), or multiresistant Enterococcus faecalis clones corre-
sponding to CC2 (ST2 and ST6), CC87 (ST87), and ST16
(152), some of which are shared by humans and farm animals
(54). Examples among Gram-negative bacteria are E. coli
clones such as O25b-B2-ST131 (113), Klebsiella pneumoniae
CC258 (ST258 and ST11), some expanded clones of other
enterobacterial species that are involved in the dissemination
of resistance to extended-spectrum cephalosporins, or selected
strains of multidrug-resistant (MDR) Acinetobacter baumannii
(155). Changes in the overall prevalence of AbR in particular
settings frequently occur because of the more or less efficient
penetration of a relatively small diversity of such high-risk
clones.
Direct fight against these clones or clonal complexes should
reduce AbR. This has occurred with Haemophilus influenzae or
Streptococcus pneumoniae. The introduction of the 7-valent
conjugated vaccine (PC7) is in fact the first and most successful
intervention in reducing AbR that has ever happened and
should constitute a model for future eco-evo strategies. In fact,
this success was due to the fact that PC7 reduces pharyngeal
colonization of resistant serotypes in humans (infected or not)
and blocks human-to-human spread of resistance (13). Tar-
geted vaccination, or immunoserum protection of human pop-
ulations at risk of being invaded by resistant clones, and then
acting as sources for novel propagations, should be considered
a current need in the prevention of AbR (31, 65, 145). Such
types of immune protection could in the future include vacci-
nation against colonization factors (for instance adhesins) of
the resistant clones (38). Modeling methods to predict the
effects of vaccination in different populations have recently
been proposed (130). Certainly other fields of research are
open for future development in therapy directed against resis-
tant clones, including the use of resistant-clone-specific bacte-
riophages. Bacteriophages have been shown to work well in
controlling bacterial dissemination when used in cocktails of
different phages, avoiding the appearance of phage resistance
(79, 98). Other possibilities are bacteria producing toxins that
kill members of the same genotype or other bacterial (probi-
otic-like) organisms with clone-interfering abilities, serving as
“Trojan horses” that interfere with the social (interactive) evo-
lution of microorganisms (21, 27; Alex Mira, personal commu-
nication).
Ecological and evolutionary links exist between AbR and
bacterial virulence (87). Virulent clones causing infections are
frequently highly transmissible, have increased risk of being
exposed to antibiotics, and consequently have the propensity of
acquiring AbR (53a, 99). Consequently, targeting virulence
might result in a decrease of antibiotic resistance. Even if they
are out of the scope of this minireview, there is a wealth of new
approaches to reduce bacterial virulence (reviewed in refer-
ences 11, 12, and 26). Examples are methods targeting type III
secretion inhibitors (1, 11, 12, 67) or quorum-sensing mecha-
nisms (74, 78, 105, 111), and drugs able to modify bacterial
master regulators influencing the expression of colonization
factors of resistant clones can be expected (77, 118). Recently,
screening chemicals against drug target enzymes predicted us-
ing a genome-scale metabolic network model has been pro-
posed (118). This approach would presumptively allow analysis
of the genome of any microbial pathogen and the development
of a systems biological strategy by using genome-scale meta-
bolic modeling and simulation for effective specific drug tar-
geting and discovery (70).
(ii) Reduction of selective environments for high-risk resis-
tant clones. Penetration of high-risk resistant clones is favored
by antibiotic agents, as they reduce the “colonization resis-
tance” of the recipient microbiota, in the classical van der
Waaij approach (132, 144). Of course, much more needs to be
known about the biological bases of suppression of invading
populations by complexes of resident populations, a problem
of systems biology (21). Metagenomics of human gut symbi-
onts reveals a set of genes critical for adaptation to the gut
environment and mechanisms for horizontal transfer of the
genes (160). In any case, the reduction in the local antibiotic
effect on indigenous microbes should be minimized. Novel
molecules enhancing the upper-gut absorption of oral antibi-
otics or decreasing its biliar excretion should be considered to
act against AbR. The strategy of destroying antibiotics in the
intestine by the uptake of specific detoxifying enzymes, as beta-
lactamases in patients treated with beta-lactam agents, or an-
tibiotic-binding substances has been proposed (http://www
.davolterra.com/rd-pipeline).
Promiscuity inhibitors. (i) Inhibitors of interbacterial dis-
semination of genetic elements. Genes encoding AbR fre-
quently spread by means of MGEs. These elements are usually
disseminated by any of the three classical bacterial DNA
transfer mechanisms: conjugation, transformation, or trans-
duction. Second-order transfer mechanisms also contribute
to this spread, as plasmid “conduction,” that is, cointegrate
formation of a nonmobile element with a transmissible one
and then resolution. Dissemination frequently occurs among
“genetic exchange communities,” which would be better
named “genetic interactive communities” as there might be
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unidirectional transfer (121). Such ensembles of bacteria fre-
quently (but not always) have ecological compatibility and
genomic similarity, which facilitates genetic transfer, homolo-
gous/homeologous recombination, expression, and subsequent
regulation (41, 121). The application of interference strategies
to genetic exchange networks, and particularly interference of
“broker clones” able to spread plasmids very efficiently in het-
erogeneous bacterial communities (42), eventually by the use
of probiotics (93) should reduce genetic promiscuity. The im-
portant point here is that the natural history of AbR indicates
that conjugation has been the predominant mechanism used by
resistance genes to appear in many human pathogens. Once
there, the genes can be dispersed further by transformation
and/or transduction. The main reason for the predominance of
conjugation might be that this process is naturally broad host
range, certainly much broader than transformation and trans-
duction (122).
(ii) Broad-host-range conjugation inhibitors. Conjugation
effects the dissemination of plasmids, conjugative transposons,
and ICEs. Moreover, most plasmids (and related elements)
conjugate using variants of the same biochemical core process.
Specifically, they all use a protein called relaxase to bring about
the conjugative replication of the DNA to be transferred and a
set of ATPases to motor the process of DNA transport. There-
fore, although other targets will be discussed below, conjuga-
tion seems to be the preferred potential target, thanks to its
universality (36, 122).
The fact that there is a single predominant mechanism of
plasmid conjugation raises the hope that broad-host-range an-
ticonjugation drugs (called COINS hereafter, for conjugation
inhibitors) can be discovered. There have in fact been impor-
tant advances in this direction. First, a high-throughput whole-
cell assay to detect and assay for COINS was developed (50).
Using this assay, a conjugation-inhibitory compound called
dehydrocrepenynic acid, an unsaturated fatty acid, was discov-
ered, establishing the proof of principle that this type of eco-
evo drugs can be found. It was also found that other polyun-
saturated fatty acids, like linoleic and linolenic acids, are also
potent COINS. Later on and using screening methods for in
vitro reactions, inhibitors were found for both relaxase proteins
(84) and one of the conjugative motor ATPases (64). Antire-
laxase compounds (biphosphonates, clodronate, and etidro-
nate) worked efficiently in vitro, were much less effective in
vivo, and presented unexpected results on cell viability (84).
Another line of research is the investigation of components of
the E. coli cell wall that inhibit conjugation of the classical
F-factor. These components were solubilized and partially pu-
rified. Up to now, their nature and potential applications are
unknown (116). Finally, there is a recently described mecha-
nism for the control of dissemination of plasmids and phages,
which is effected by regularly interspaced short palindromic
repeats (CRISPRs) (86, 127) These DNA elements, when lo-
cated in the recipient bacteria, interfere with conjugation and
plasmid transformation, for instance in Staphylococcus (86)
The range of their activities is necessarily narrow, as they use
specific sequences that have to match perfectly to the target to
activate the nucleases.
(iii) Specific conjugation inhibitors. As in the case of “high-
risk clones” (discussed above), we can also consider “high-risk
plasmids,” plasmids that efficiently disseminate among bacte-
rial organisms (particularly among “genetic interactive com-
munities”) and harbor dangerous resistance genes (22, 121,
122, 135). Advances in identification of such target MGEs
might provide alternatives directed to specific conjugation sys-
tems. (i) Some bacteriophages specifically bind different types
of pili involved in bacterial conjugation (98). In all cases, the
phages target specific pilus types, and thus, their range of
targets is limited. However, using the same principle as in
antibacterial phage treatment, enlargement of the spectrum of
inhibition could be expected for a cocktail of phages, each with
specificity for a major potential target, (79). Similar antipili
strategies could be devised with the use of aptamers (69, 104).
(ii) Another possibility is based on entry exclusion proteins, a
diverse family of small proteins known to be efficient inhibitors
of conjugation, which could be considered for future anticon-
jugation vaccines or aptamers developed by synthetic biology
(57). (iii) Techniques that exploit the phenomenon of DNA
restriction could be used. Restriction systems can be added to
inhibit plasmids (perhaps in combination with the eex genes) to
broaden and potentiate the mechanisms of inhibition (84, 141).
(iv) Methods that inhibit modulators of bacterial conjugation
could be used. Some bacteria, like Enterococcus faecalis, pro-
duce pheromones that are necessary to induce plasmid conju-
gation. Antipheromone drugs or vaccines could limit the ex-
pansion of particular plasmids. Of course, similar strategies
could be devised to decrease bacterial transformation, partic-
ularly targeting competence proteins and/or recognition se-
quences in transformed DNA. (v) Some plasmids, like plasmid
F, have inducible transfer systems that are usually repressed
(fertility inhibition systems). Inhibitors of the mechanisms of
induction of fertility should obviously decrease plasmid pro-
miscuity.
Plasticity inhibitors. The evolution of AbR depends on the
mechanisms involved in genetic variability, as mutation and
recombination. Frequent recombination-modularization events
(4, 41) contribute to the building up of complex genetic struc-
tures in which resistance genes are located. Such platforms
often include other resistance genes, thus increasing the ability
of the genetic ensemble to be selected by various antimicrobial
agents.
(i) Recombinase inhibitors. Inhibition of recombination is a
hypothetical target that should decrease the acquisition and
integration of new resistance genes and platforms, delaying the
evolution of the complex genetic structures involved in multi-
resistance. RecA protein plays important roles in a number of
DNA recombination and repair processes, including homolo-
gous recombination and recombinational DNA repair. Small
molecule RecA inhibitors may sensitize bacteria to established
antibacterial agents and also prevent the development and
acquisition of genes conferring drug resistance. For instance,
tandem-gene amplification, a key first step for evolving resis-
tance, is RecA dependent (Dan Andersson, personal commu-
nication). In Bacillus subtilis, DNA uptake machinery requires
RecA for integration of homologous donor DNA into the
recipient chromosome, while plasmid establishment, which is
independent of RecA, requires at least RecO and RecU (68).
The search for site-specific recombination inhibitors (focused
on transposon Tn3) started a quarter of century ago (49).
Possible metal-chelate RecA inhibitors have been proposed as
transition metal complexes (based on metal-dependent initia-
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tion of RecA aggregation), nucleotide analogs, structured pep-
tides, and polysulfated naphthyl compounds (75, 76, 151). Un-
fortunately, these molecules are not cell permeable or have a
pleiotropic effect on live bacteria. Recently, a high-throughput
target-based screening approach has permitted the identifica-
tion of a new class of small, permeable compounds that can
attenuate the SOS response in living bacteria (117, 150, 151),
Conjugative plasmids have a natural RecA inhibitor, PsiB
(108), and research in natural systems of controlling recombi-
nation will eventually be of interest. Finally, investigation on
HIV-1 has yielded a large number of integrase inhibitors,
which eventually could be tested for inhibition of resistance
gene acquisition by genetic platforms (58; J. C. Gala´n, personal
communication).
(ii) Mutation inhibitors. The possibility of controlling mu-
tations due to either DNA damage repair or reactive oxygen
species (ROS)-forming systems as a novel therapeutic strategy
has already been proposed (25, 46, 72, 138). Most RecA in-
hibitors discussed in the above paragraph should have an in-
hibitory effect on SOS induction, therefore reducing the mu-
tational capabilities of the bacterial cell. Cleavage of the SOS
repressor LexA is induced by antibiotic DNA damage resulting
from superoxides resulting from the metabolic changes in-
duced by antibiotic action (46, 73). LexA cleavage produces
the derepression of RecA and the SOS-regulated polymerases
Pol II, Pol IV, and Pol V, promoting recombinational and
mutational changes leading to AbR. It has been suggested that
inhibition of these proteins or prevention of their derepression
by inhibition of LexA cleavage with suitably designed drugs
might represent a fundamentally new approach to combating
the emerging threat of AbR bacteria (24). The reduction in
the intracellular concentrations of mutagenic compounds, as
DNA-damaging superoxides, should also reduce mutation
rates. The proof of concept is provided by the observation that
the overexpression of a norM multidrug and toxin extrusion
(MATE) family efflux pump in bacteria protects against reac-
tive oxygen species and provides antimutability (62). Combi-
nation therapy coupling antibiotics with antibiotic-enhancing
bacteriophage engineered to target SOS (by expressing un-
cleavable LexA variants) or non-SOS gene networks (by over-
expressing SoxR of the superoxide-responsive system SoxSR)
significantly increases survival in antibiotic-treated animals and
has been suggested as a promising antimicrobial approach (46,
83). Drugs that might increase bacterial superoxide dismutases
could have similar effects. Extracellular stress-induced muta-
tion (and eventually resistance gene amplification) also de-
pends on RpoS, sigma 32, and sigma E (59). The possibilities
of upregulation of the methyl-mismatch repair (MMR) sys-
tems as a way of decreasing mutational adaptation are poor, as
even in multicopy, the genes of the MMR system scarcely
influence mutation rates (56).
Persistence inhibitors. (i) Decontamination of high-risk
clones. Eco-evo drugs and strategies directed to reducing the
absolute number of high-risk clone cells could have important
consequences in fighting AbR. A high-risk clone is a multi-
drug-resistant clone with highly efficient transmission and/or
maintenance among humans or animals. Even if it is beyond
the scope of this minireview, it is obvious that hospital hygiene,
antibiotic, and disinfectant policies and containment activities
contribute to the hospital decontamination of high-risk resis-
tant clones, but as stated before, such an approach has had
limited success, particularly in heavily contaminated areas (17).
A number of antipenetration eco-evo drugs might reduce
persistence, as clone-directed vaccines, antisense oligomers
targeting clone-specific genes (discussed below, antigene ap-
proaches), specific immunosera, phages, or substances de-
creasing the selective activity of antibiotics, for instance on the
intestinal microbiota (see above). A number of bacterial traits
involved in persistence are frequently considered “virulence
traits,” so that advances in some of the new molecules targeting
virulence might also influence bacterial persistence of high-risk
clones (12, 26). Another interesting possibility will be to use
clonal interference strategies. E. coli probiotic strains produc-
ing mixtures of microcins (small antibiotic peptides), such as
microcins M and H (142) could be good potential candidates
for this task. Genetic modified organisms (GMOs) carrying
amensalistic substances have been already used in experimen-
tal remediation with Pseudomonas putida (94).
(ii) Decontamination of high-risk MGEs. The decontamina-
tion of high-risk MGEs is undoubtedly a difficult objective.
Reduction in the absolute number of high-risk clones harbor-
ing MGEs does not necessarily ensure a significant reduction
of high-risk mobile elements. Such MGEs might be harbored
within multiple species and clones forming genetic exchange
communities (121), thus acting as potential reservoirs for the
maintenance of MGEs. An important recent approach is the
possible use of bacterial probiotic clones that interfere with
plasmid exchange networks but that are unable to be invaded
by high-risk MGEs (21, 107). A more straightforward approach
could be a direct attack on MGEs, like plasmids, that could
become “the Achilles heel of drug-resistant bacteria” (153),
reconverting resistant bacteria into susceptible ones. The
history of “plasmid curing approaches” began more than 30
years ago and is based on the observation of plasmid elim-
ination by acridine dyes (recently confirmed with 9-amino-
acridine), ethidium bromide, or sodium dodecyl sulfate (129).
More recently, two main approaches have been applied for
“plasmid decontamination” of bacterial populations. The ear-
liest (but still active) line of research has investigated antiplas-
mid compounds that take advantage of the differential DNA
topology in plasmids or the bacterial chromosome and/or
the membrane-plasmid DNA interaction during replication.
Plasmid DNA exists in a superhelical state more frequently
than chromosomal DNA. For instance, heterocyclic com-
pounds bind better to supercoiled plasmids, differentially in-
hibiting their replication (129). Tricyclic molecules, such as
phenothiazines (as promethiazine), dibenzoazepines, dibenzo-
cycloheptene derivatives, and some stereoisomers, have been
able to cure E. coli plasmids in vitro (90). The relatively low
efficiency in plasmid elimination might be increased by the
association with calmodulin or proton pump inhibitors (128).
Plumbagin, a simple plant secondary metabolite, seems to
eliminate stringent, conjugative, multidrug-resistant plasmids
from several strains (102).
The second and more recent approach exploits mechanisms
involved in natural plasmid elimination (2) and is discussed
below in more detail. Natural plasmid loss occurs essentially by
the following mechanisms: (i) excessive biological cost for the
host cell in maintaining the MGE, so that spontaneously plas-
mid-free cells overcome plasmid-bearing cells; (ii) plasmid in-
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compatibility, when plasmids of the same incompatibility group
(depending on their rep sequences, the replication machinery)
do not stably cosegregate to a daughter cell; (iii) plasmid fail-
ures in partition and multimer resolution, eventually giving rise
to plasmid-free daughter cells; (iv) when bacteria lose their
protection against toxins produced by plasmids themselves
(toxin-antitoxin systems). Indeed, each one of these mecha-
nisms might provide clues for the development of future MGE
decontamination drugs.
Plasmid cost enhancers. The reasons behind plasmid bio-
logical cost remain poorly investigated. It is known that such a
cost frequently peaks after the acquisition of a novel plasmid
for the host organism, and the cost is progressively reduced
during coexistence time, in a kind of “plasmid domestication”
(35). Domestication probably results from a complex rewiring
of the cell metabolism involving the presence of the plasmid.
The cost frequently increases upon expression of the resistance
gene (for instance, after transcriptional induction), and this
cost is variable for different genes (96). This suggests that there
could be a window of opportunity for cost enhancer drugs
when we try to suppress the spread of a plasmid carrying
particular genes from a successful penetrating strain to other
strains of different clones or species. A more sophisticated
approach could be the artificial introduction of a selectable
gene (for instance a gene encoding a nonabsorbable, nontoxic,
but nontherapeutical antimicrobial agent or a gene encoding a
natural amensalistic substance, bacteriocin, or microcin) in a
bacterial community by means of particularly efficient plasmid
vehicles or biodrugs, using the acquisition of that gene in the
presence of the selector to increase the overall cost of the
recipient plasmids.
Exploiting plasmid incompatibility mechanisms. The ex-
ploitation of the mechanisms of plasmid incompatibility has
been explored (37, 139, 153). In this case, the plasmid replica-
tion machinery is an obvious target, for instance using com-
pounds able to reduce the intracellular levels of RepA repli-
case. These levels are determined by its interaction with a small
RNA, RNAI, whose conformation can be altered by drugs,
such as apramycin, at least in incompatibility IncB systems
(139). An apparent limitation to such an approach is the pos-
sible rapid emergence of plasmid elimination-resistant mutants
by mutational changes in the Rep sequences. As in the previ-
ous case, we can imagine the artificial introduction and selec-
tion within a particular bacterial community of a plasmid en-
coding a nontherapeutic antimicrobial resistance trait, which
could eventually be able to displace plasmids of the same
incompatibility group. The introduction and maintenance of
the resistance-curing plasmid-selecting agent would probably
require the administration of a nontherapeutic compound se-
lecting for the new plasmid.
Exploiting toxin-antitoxin systems. A number of clinically
important plasmids containing antibiotic resistance genes have
toxin-antitoxin (TA) systems. The plasmid simultaneously pro-
duces a stable toxin able to kill the bacterial host and a labile
antitoxin, so that if the plasmid is lost, the antitoxin is not
longer produced, and the toxin that remains in the bacterial
cytoplasm induces cell death. This kind of host capital penal-
ization for plasmid loss, which has also been called “mafia
strategy” (96), forces the coexistence of the plasmid and the
cell harboring the plasmid, facilitating metabolic networking
between both replicons, and finally leading to plasmid domes-
tication. Compounds that can increase the production of the
toxin, decrease the production of the antitoxin, or interfere in
the toxin-antitoxin interaction will result in the loss of cells
containing the plasmid (40, 81). A possible limitation of this
strategy is the presence of toxin-antitoxin systems in the bac-
terial chromosomes. For instance, induction of chromosomal
TA genes results in an increase of bacterial cells presenting a
“persistence” phenotype, with cells that neither grow nor die in
the presence of antimicrobial agents but that are able to reas-
sume division once the exposure is over (43, 80). Obviously, in
the absence of death or replication, plasmid loss would be
severely limited.
Finally, partition and multimer resolution could theoreti-
cally be considered processes with potential antiplasmid tar-
gets, but as far as we know, nothing has been proposed or
published on this possibility. It is of note that many of the
possible antiplasmid resistance drugs will have a very limited
target, a plasmid or a plasmid family. The possible utility of
such products will be specific plasmid decontamination, a goal
that fits well with targeted eco-evo therapy.
Decontamination of high-risk genes. The possibility of de-
contamination of a bacterial system of particular AbR genes or
eventually critical genes for the maintenance or spread of
MGEs carrying resistance determinants has also been exam-
ined. The use of antisense oligomers (ASOs) is a promising
technology for treating viral and bacterial infections (148). A
major class of ASO compounds, phosphorodiamidate morpho-
lino oligonucleotides (PMOs), target bacterial genes known to
be essential for growth or virulence have recently been proved
efficient in treating chronic infections caused by multidrug-
resistant Burkholderia species complex (26, 61). A similar
strategy could be applied to inactivate antibiotic resistance
genes (156). Antisense strategies directed toward specific re-
sistance genes (such as aac(6)-Ib) have been successfully ap-
plied to reduce AbR (amikacin resistance) (125). Recently,
small interfering RNAs have also been considered “therapeu-
tic targets” for gene silencing (23, 120), a concept of potential
application to AbR. Note that inhibiting resistance at the nu-
cleic acid level has been hitherto considered only to prevent
resistance gene expression, the resistance phenotype, during
therapy. Decontamination of resistance genes will require di-
rected gene knockout by mutagenesis or gene disruption or
allelic replacement by susceptible genes, which is a feasible in
vitro approach, but it is difficult to foresee the methods to
achieve effective gene replacement in the field and to select for
the resulting susceptible variants.
Selection for antibiotic-susceptible bacterial organisms. In-
deed, many of the strategies and possible eco-evo therapeutic
approaches discussed above should produce a selection of an-
tibiotic-susceptible organisms. However, other possibilities for
very active selection should be considered. Let us imagine an
antibiotic X that is active only upon a chemical modification
that is available by the action of an enzyme that inactivates
another antimicrobial agent Y, whose clinical use is aimed to
be preserved. Only Y-resistant bacteria will be killed by the
antibiotic X. The expected effect is selection for susceptibility.
In a more classical way of thinking, the introduction of new
antibiotics in hospitals might have a beneficial effect in the
levels of resistance to previously used antibiotics, of course
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under the condition of non-cross-resistance. In some cases, the
evolution toward resistance to a given antibiotic increases sus-
ceptibility to another one, and vice versa, an antagonistic
pleiotropy phenomenon (15, 97). Finally, we cannot exclude
the possibility that a number of refined bacterium-decontam-
inating procedures (heat, radiation, novel biocides, or others)
could be tuned to target preferentially antibiotic-resistant or-
ganisms. At this time, this seems a difficult task, but it must be
mentioned.
Eco-evo or eco-evo-devo? Microbiosphere restoration. The
eco-devo (evolutionary developmental biology) approach ex-
plores the mechanistic relationships between the processes of
individual development (such as embryogenesis) and pheno-
typic change (such as morphotypes) during evolution (133). If
a real “development” is rare in the individual bacterial cells, a
kind of development occurs in complex microbial systems as-
sociated with humans, such as the gut microbiota, which can be
considered a collective individual at a supraspecies level of the
biological hierarchy, evolving (changing) with the host from
birth to senescence. The eco-evo-devo (ecological evolutionary
developmental biology) approach (136) perspective integrates
development biology with ecology and evolution. Indeed, if we
could influence the structure and development of the micro-
biota associated with humans, it should have an effect on the
networking of genetic interacting communities sharing, mobi-
lizing, and evolving resistance genes and platforms, and finally
on AbR. Little has been done to correlate microbiotic struc-
ture with AbR, but there is certainly something important to
delve into. We can consider the possibility of “microbiotic
transplantation” with susceptible organisms early in life or
after appropriate decontamination procedures. For such a
purpose, we need to know more about the microbiota struc-
ture and its relations with the host genetics and environ-
ment. However, considering the speed of evolution of AbR,
the time might have arrived to start thinking about biobanks
able to preserve susceptible microbiotic ensembles for fu-
ture biorestorative interventions.
Eco-evo interventions: indications, ethics, models, and out-
comes. The main set of problems for the development of eco-
evo interventions is related to the need for a change in society
about the concept of “what is a drug.” From drugs that cure
patients to drugs that cure a sick environment, there is cer-
tainly a big jump both for the industry and regulatory agencies.
As in the case of sick patients, sick environments should be
diagnosed before treatment. We have here an important chal-
lenge—what is a sick environment, in our case, what is a sick
environment because of antibiotic resistance? In other words,
could we establish “indications” for eco-evo local interven-
tions? A typical case could be a intensive care facility (or a
farm) where a particular clone of a pathogenic organism has
been isolated with a novel, potentially dangerous mechanism
of resistance encoded by a gene hosted by a particular integron
located in a particular transposon, hosted by a highly transmis-
sible plasmid. We are also aware (thanks to multilevel epide-
miology tools) that the plasmid has been transferred to com-
mensal microorganisms and the clone has been transferred
from the index patient to other patients. Another possibility
are more-restricted sick environments, such as the bronchial
spaces in cystic fibrosis patients, where prevention of hyper-
mutation or recombination and/or anticlonal vaccination could
be used. These are sick environments for antibiotic resistance.
Current clinical trials with new drugs under development are
oriented almost exclusively to measure their effects on individ-
uals (human volunteers or sick patients). Eco-evo interven-
tions are mostly (but not exclusively) oriented to modify the
“risk landscape,” in our case for AbR. We have reviewed here
and in Table 1 a number of possibilities for controlling the
ecology and evolution of AbR inside and outside the human
host. Indeed, eco-evo interventions to reduce AbR in the en-
vironment should be carefully controlled using environmental
risk assessment standards but refined to be able to detect
small-scale but eventually important changes. Assessment of
eco-evo interventions will require the development application
of novel technologies for investigating the appropriate out-
comes. The quantification of the effect of eco-evo interventions
in changes in the frequency of AbR in individual patients (such
as strongly immunosuppressed patients), small areas (such as
intensive care units), larger organizations (such as hospitals,
long-term care facilities, and farms), or the community will also
require appropriate tools. An important issue is the possible
adverse events of eco-evo interventions trying to limit AbR. A
number of the possible compounds discussed in this minire-
view, particularly those aiming to control the molecular mech-
anisms involved in mutational or recombinational events, will
probably have at this time low selectivity, as human cells have
similar targets. Undesirable and even unexpected effects on
natural microbial ecosystems should be also considered. For
instance, populational replacements could be provided (as with
the PC7 vaccine in S. pneumoniae populations). If nonspecific
plasmid-targeting drugs are used, their impact on the produc-
tivity and biodegradation capability of environmental microbi-
ota should be considered. Indeed, there is a possibility of using
collective animal models (experimental farms and their en-
vironment) to test eco-evo interventions and using the data
obtained to feed appropriate mathematical models. In this
respect, it is of note that many of the possible eco-evo
interventions could be conceived as very targeted (narrow
spectrum), focusing for instance on particular genetic ex-
change communities, clonal complexes, strains, plasmids, or
genes. Such a “biosurgical” approach should also be perme-
ated into the conservative minds of the pharmaceutical in-
dustry and regulatory agencies.
Concluding remarks. It is our hope that this minireview will
help the scientific and industrial communities to realize that
the eco-evo perspective offers a number of potential outcomes
that can be used to slow down the evolution and dissemination
of AbR and eventually to partially restore susceptibility in
particular environments. With a few exceptions (anticlone vac-
cination), at this time we have only a small number of prom-
ising products and almost no experience in the possible effects
of the eco-evo strategy in the real world, but interest has
started to rise in the pharmaceutical and ecological industry. In
the years to come, relevant laboratory and field experiments
should be carried out to prove that any of these approaches can
be effective in reducing the frequency or limiting the dissemi-
nation of the genes and genetic platforms involved in AbR.
However, our work will be inconsequential if it does not con-
tribute to permeate the thinking of scientists and regulatory
agencies with the idea that there is a need to consider a space
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for a new type of “drugs” as agents of future eco-evo interven-
tions to decrease AbR. Finally, it should be clear once more
that AbR is a “model problem,” and similar eco-evo strategies
could be probably applied in the future for maintenance of a
healthy interaction between humans and microbial systems in
a rapidly changing biosphere.
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